Plasmid DNA Contamination, SB40 Promoter, Bacterial Plasmids, Antibiotic Resistance Genes, Manufacturing Variability , Quality Assurance, Quality Control, Pharmaceutical Standards, Gene Therapy Classification, Genomic Laura Braden testified that COVID-19 mRNA injections lacked adequate quality control, contained variable and raised concerns regarding potential genomic integration, persistence in the body, biodistribution variability She stated that manufacturing variability could result in inconsistent biological outcomes between injections

COVID-19 vaccine quality control, spike protein variability, biodistribution, genomic integration potential One Line Summary A clinical biochemistry professor argues that mRNA vaccine quality variability and spike He stated that published analyses indicated variability in mRNA integrity, with some batches containing He further presented data suggesting variability in spike protein expression among individuals, including He argued that variability in mRNA length and protein expression results in inconsistent dosing and immune

EMA regulatory flags, conditional marketing authorization, gene therapy classification dispute, batch variability standards, and safety evaluation processes for mRNA COVID-19 vaccines. , variability in batch integrity, and outstanding obligations related to spike protein characterization nanoparticle stability, potential contamination with residual DNA, endotoxin, and other impurities, and variability in mRNA concentration within production vats.

Transcript protein kinase research, spike protein signaling, lipid nanoparticle delivery, biodistribution variability , mRNA translation persistence, off-target cellular effects, inflammatory pathway activation, kinase analyzes spike protein signaling effects and raises concerns about off-target molecular consequences of mRNA He testified that biodistribution studies indicate the lipid nanoparticle–mRNA complexes may not remain He raised concerns regarding variability in mRNA translation levels, persistence of spike protein expression

Witness Testimony Keywords from Transcript mRNA vaccine regulation, gene therapy definition, EMA exclusion -19 Response in Canada; November 2023 Main Topic Regulatory classification and safety evaluation of mRNA One Line Summary A French pharmacist-biologist argues that mRNA COVID-19 vaccines meet definitions of She argued that, based on definitions from the FDA and European Medicines Agency (EMA), mRNA vaccines phases and limited dose-optimization studies, and referenced concerns about product integrity and batch variability

Transcript renin-angiotensin system, ACE2 receptor binding, AT1R overactivation, spike protein effects, mRNA enhancement, integrin RGD motif, furin cleavage site, genetic polymorphism RAS, manufacturing batch variability Regarding mRNA vaccine technology, Dr. , potential translation variability, and the possibility of truncated or heterogeneous spike protein production due to manufacturing variability.

Witness Testimony Keywords from Transcript mRNA platform history, lipid nanoparticle inflammation, spike Robert Malone MD Physician and mRNA Technology Researcher Expert Witness ID: NCI-W-040 Hearing Toronto vaccine safety, manufacturing quality, pediatric risk–benefit, and allegations of coordinated psychological One Line Summary mRNA pioneer Dr. Malone raised concerns about manufacturing quality, alleging evidence of plasmid DNA contamination, truncated

5.7.1 mRNA Vaccines, Public Health, and Safety Concerns 5.7 Health and Medical Safety 5.7.1 mRNA Vaccines , Public Health, and Safety Concerns Recommendations Suspend mRNA Vaccine Roll-out: Implement an immediate moratorium on mRNA vaccines until independent safety verification is conducted. 2. Support Research and Accountability: Fund long-term studies on the effects of mRNA vaccines.

4.7.1 mRNA Vaccines, Public Health, and Safety Concerns 4.7 mRNA Vaccines, Public Health, and Safety Witnesses pointed to inconsistencies in safety monitoring and quality control, which undermined confidence There is also evidence that ‘misreading’ of the vaccine mRNA may produce variant S proteins whose effects Concerns About “Shedding” Following vaccination, viral mRNA or mRNA fragments have been shown to occur presence of DNA contamination in vaccine vials raised additional red flags about the manufacturing and quality

physician suspension, College investigation, regulatory retaliation claim, excess mortality assertion, mRNA William Makis testified that mRNA vaccines are linked to sudden deaths, aggressive cancers, and immune virtually regarding what he described as widespread vaccine-related injuries and deaths following COVID-19 mRNA He asserted that public health authorities ignored early treatment options and that mRNA vaccine technology He expressed concern about ongoing booster campaigns and called for immediate cessation of mRNA vaccine

Witness Testimony Keywords from Transcript virology expertise, viral evolution theory, mRNA platform Efficacy of the COVID-19 Response in Canada; November 2023 Main Topic Scientific critique of COVID-19 mRNA One Line Summary Virologist presents concerns about mRNA vaccine platform design, regulatory approval virology and molecular genetics, testified regarding concerns about the design and implementation of mRNA

Typically, the genetic variability of coronaviruses based on RNA genomes confers only partial immunization vaccines: new mRNA vaccines for the variant du jour could be made available more readily. This was not the case, as was evident by the numerous quality issues with truncated spike mRNA sequences Also, it‘s possible to minimize variability of outcomes due to genetic and epigenetic factors by selecting of RNA with the variant du jour.